With the FDA’s approval of Spravato, an intranasal esketamine medication for treatment resistant depression, Maui Mind Care serves as the island’s first center for administration. Like TMS therapy, Spravato is ideal for patients who have failed to find relief with first line medicinal treatments.
Application must take place under medical supervision, and a two-hour observation is required after each dose. Acute courses of treatment are 2-3 times a week for 3-4 weeks, with a gradual taper. Patients are unable to drive for a period of time after each dose. So, assistance with transportation is needed. Contact us for more information.
Common side effects include: nausea, dizziness, blood pressure changes, and the potential for dissociation.